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T-CELL-MEDIATED CONCOMITANT IMMUNITY TO 
SYNGENEIC  TUMORS 
I. Activated Macrophages as the Expressors of Nonspecific Immunity to 
Unrelated Tumors and Bacterial Parasites* 
By ROBERT J.  NORTH  ANY DAVID P.  KIRSTEIN 
(From The Trudeau Institute, Inc., Saranac Lake, New York 12983) 
It is now generally agreed that most syngeneic tumors possess tumor-specific 
transplantation antigens and are  immunogenic to a  larger or lesser degree. 
Their immunogenicity (reviewed in reference 1) is evidenced by the numerous 
demonstrations of a  state of specific immunity to the growth of a  tumor cell 
challenge in animals that have been immunized with injections of subtumori- 
genic doses of living tumor cells, with injections of lethally irradiated tumor 
cells, or that have had their primary tumors removed by surgery or ligation. 
Additional  evidence for  the  immunogenicity of transplantable  as  well  as 
autochthonous tumors  is  illustrated  by  examples  of concomitant immunity 
(reviewed in reference 2) in which animals bearing large progressive tumors 
display a paradoxical state of immunity to the growth of a second implant of the 
same tumor. That the generation of concomitant immunity may be a common 
consequence of neoplastic growth is  also  suggested by the  large  number of 
publications (1, 3, 4) which show that tumor-bearing humans as well as tumor- 
bearing animals can acquire leukocytes that are specifically cytotoxic for tumor 
cells in vitro. Indeed, the large number of examples of this phenomenon is in 
itself reason for suggesting that concomitant immunity may represent a fairly 
universal natural response to solid neoplastic growth, and may play a signifi- 
cant part in determining the outcome of certain types of anti-cancer therapy. 
Again, a good case has been made (5-7) for proposing that concomitant immu- 
nity functions to retard the spread and growth of metastases. 
There is evidence (6) that concomitant immunity to syngeneic tumors is cell 
mediated and specific. More recent evidence (8) contradicts this, however, by 
showing that concomitant immunity to certain murine fibrosarcomas displays a 
significant element of nonspecificity as judged by the host's capacity to retard 
the growth of antigenically unrelated tumors. It has been suggested on the basis 
of this and other evidence  (9,  10)  that  macrophages may participate  in the 
expression of this form of anti-tumor immunity. 
This paper provides evidence to support the view that concomitant immunity, 
although T-cell mediated, is capable nevertheless of suppressing, to a  limited 
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extent, the growth of apparently unrelated tumors. More importantly, it will 
show that the generation of concomitant immunity to the syngeneic murine SA1 
fibrosarcoma is  associated with the  concordant development of an activated 
macrophage system which supplies the host with a  greatly enhanced, macro- 
phage-mediated capacity  for resisting  infection with  the  bacterial  parasite, 
Listeria monocytogenes. The results give credence to the view that macrophages 
may have evolved to serve the common role of guarding against colonization by 
neoplastic cells as well as by microorganisms. 
Materials and Methods 
Mice.  AB6F1 (A/J × C57BL/6J) mice of both sexes were mostly employed. They were produced 
from parental  A/J and  C57BL/6J  breeding stock  obtained from The Jackson  Laboratory,  Bar 
Harbor, Maine. 
Tumor.  The SA1  spindle cell sarcoma  syngeneic in A/J mice was originally purchased from 
The Jackson Laboratory. It is passaged weekly intraperitoneally in the ascites form in syngeneic 
mice.  All  of the experiments  reported here,  however,  were  performed  with  a  single  stock  of 
biofrozen tumor cells. They were obtained by injecting a  large number of mice intraperitoneally 
with 106 SA1 cells and harvesting tumor cells 7 days later in heparinized phosphate-buffered saline 
(PBS)2  They were washed twice in PBS,  resuspended to  107/ml in minimal essential medium 
(MEM)  containing 20%  fetal  calf serum  and  20%  dimethyl  sulfoxide,  and biofrozen in  small 
aliquots and stored in liquid nitrogen. For each experiment an aliquot was thawed,  washed in 
PBS, and the cells grown intraperitoneally for 7 days in AB6F1 mice before being harvested and 
suspended at an appropriate concentration in PBS for initiating foot pad tumors. Tumor cells were 
injected in a vol of 0.05 ml with a 30 guage needle. In most cases primary tumors were grown in the 
left-hind foot pad, while concomitant immunity against a  tumor cell challenge was measured in 
the contralateral foot pad. The growth of the primary and challenge tumors was monitored against 
time by measuring increases in the dorseventral thickness of the foot with dial calipers. 
Syngeneic benzpyrene- and  methylcholanthrene-induced fibrosarcomas designated BP3  and 
MC5, respectively, were employed in specificity studies. They had undergone 15 mouse passages at 
the time of the experiments. 
Irradiation.  Whole-body gamma  irradiation was performed in a  cesium-137  irradiator that 
generated a  midphantom dose of 35.5 rads/min. 
T-Cell-Deficient  Mice.  Mice  were  made  T-cell-deficient  (THXB)  as  adults  by  thymectomy 
followed 7 days later by lethal (900 R) whole-body gamma irradiation. They were infused intrave- 
nously with  l0  s syngeneic bone marrow cells immediately after  irradiation,  and employed in 
experiments 4-6 wk later. Mice treated in the same way except that they were sham-thymectomized 
(XB) served as controls for the effect of irradiation. 
Tumor Neutralization  Test.  The anti-tumor activi,ty of cells from the lymph node (popliteal) 
draining the site of the primary tumor was investigated with the in vivo Winn neutralization test 
(11). This involved mixing either "immune" or normal lymph node cells with tumor target cells at 
various lymphocyte to target cell ratios, injecting the mixture in a vol of 0.05 ml into the hind foot 
pads of normal test recipients, and after tumor growt  h  at this site with dial calipers. Lymph node 
cells were obtained from normal controls and 10-day tumor-bearing mice. The nodes were finely 
diced into small pieces which were gently pushed through a  200 mesh stainless steel screen into 
PBS. They were then passed through six layers of surgical gauze to remove clumps, washed three 
times in PBS, and suspended at an appropriate concentration in PBS for mixing with tumor cells. 
For  some  experiments  lymph  node  cells  were  depleted  of adherent  cells.  This  was  done  by 
suspending then at 107/ml in MEM containing 10% fetal calf serum, and incubating them in an 
atmosphere of 5% CO~ in air for 2 h  at 37°C in large (150-mm diameter) plastic Petri dishes under 
conditions where there was no competition for space on the substratum.  The nonadherent cells 
were collected, washed, and suspended in PBS for the neutralization test. 
1  Abbreviations used in this paper: PBS, phosphate-buffered saline; THXB, T-cell deficient; XB, 
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Treatment  with Antisera.  AKR anti-C3H0 serum was obtained  from AKR mice which had 
been given four weekly intravenous injections of 10  s CBA thymocytes. The serum was absorbed 
with AKR thymocytes (5  ×  107/ml of serum), heat inactivated at 56°C for 20 rain, and stored at 
-20°C until required. The specificity of the antiserum was tested by absorption with brain tissue 
as previously described (12). Lymph node cells at 2 ×  107/ml were incubated at 37°C for 30 min in a 
1:5 dilution of the antiserum in PBS, and then in the same dilution of agarose-absorbed guinea pig 
serum  in  PBS  for 30  rain  at  37°C.  The  cells were then  washed  and  resuspended  in  PBS for 
functional testing. 
The Ig fraction of rabbit anti-mouse Ig serum was purchased in a lyophilized form from Miles 
Laboratories,  Inc.,  Miles Research  Div.,  Kankakee,  Illinois.  The  lyophilized preparation  was 
made up to 520 ~g antibody protein/ml in PBS. Lymph node cells were suspended in this at 5 × 107/ 
ml and incubated at 37°C for 30 min. They were then treated in the same way with guinea pig 
serum as described above. Normal AKR serum served as a control for anti-0 serum, and normal 
rabbit serum as a control for rabbit anti-mouse Ig. 
Antibacterial resistance.  The systemic generation of macrophage-mediated, nonspecific, anti- 
bacterial resistance in tumor-bearing mice was measured against time by determining changes in 
their capacity for inactivating a standard  104 intravenous inoculum of the intracellular bacterial 
parasite,  L.  monocytogenes.  Changes  in  anti-bacterial  resistance  during  tumor  growth  were 
expressed as changes in loglo resistance which were obtained by subtracting the 24-h growth of the 
organism in the livers of tumor bearers from its 24-h growth in the livers of  controls. Spleen counts 
were also obtained but not included in the results. L. monocytogenes  (strain EGD) was passaged in 
mice, grown in trypticase-soy broth,  and stored in small aliquots at -70°C. The thawed aliquots 
were prepared for intravenous inoculation as described previously (13). Bacteria were enumerated 
by plating 10-fold serial dilutions of  whole liver and spleen homogenates on trypticase-soy agar. 
Results 
Time-Course of  Development.  Fig. 1 shows the growth of a standard 106 SA1 
tumor cell challenge in the right-hind foot pad given on days 3, 6,  9, or 12 of 
growth of a primary tumor initiated with 105 tumor cells in the contralateral foot 
pad. It can be seen that a significant level of anti-tumor resistance against the 
challenge implant was not expressed until 6 days ai~r initiating the primary 
tumor, and that the level of concomitant resistance increased thereafter. Thus, 
whereas growth of the challenge given on day 6 was only partially inhibited, 
growth of the same sized implant given on day 12 was completely inhibited. It 
will be noted, in addition, that the progressive increase in the level of immunity 
occurred during rapid growth of the primary tumor. Challenges were not given 
beyond day 12 because there was not enough time to follow the growth of the 
challenge before the mice began dying on day 18 from a massive primary tumor 
burden and multiple lymph node metastases. 
Fig. 2 serves to show that the results of concomitant immunity studies partly 
depend on the size of the challenge implant. It can be seen that when 10-day 
tumor bearers were challenged with 105 , 105, or 107 tumor cells, it was only the 
105 challenge that was completely inhibited from growing, although significant 
immunity was expressed against the larger implants. Concomitant immunity, 
therefore, is not absolute, and its apparent strength and rate of  development are 
a reflection of the size of the challenge implant. 
Because most of the experiments reported in this paper were performed in 
semisyngeneic AB6F1 mice, it was necessary to show that comparable levels of 
concomitant immunity  were generated by syngeneic AJJ mice. That this was the 
case is shown in Fig. 3 where it can be seen that the 10  n  tumor cell challenge was 
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Fro.  1.  Development of concomitant immunity during growth of a primary foot pad tumor 
initiated with 10  s tumor cells. The primary tumor (large graph) showed a latency period of 
about 4 days before progressive tumor growth became manifest. The growth of a standard 
10  6 challenge implant given in the opposite  foot on days 3, 6,  9, and 12  (enclosed  graphs) 
shows that the capacity to inhibit the growth of the challenge increased with progressive 
growth of the primary tumor. Means of five mice per time point. 
foot pad  tumors.  Since this  result  was taken  from  a  time-course  study that 
showed the same rate  of development as Fig.  1,  it is safe to assume that the 
results obtained with F~ hybrids also apply to the syngeneic system. 
Effect  of T-Cell Deficiency.  It  was  found  that  mice  made  T-cell-deficient 
by thymectomy and gamma irradiation,  and protected with bone marrow cells 
developed a  much  lower level  of concomitant  resistance  than  tumor-bearing 
irradiated  control mice. It can be seen in Fig.  4 that in contrast to the strong 
resistance generated  against  a  106 implant  by tumor-bearing  controls,  THXB 
mice displayed only marginal resistance to the growth of this size implant given 
on day 9 of primary tumor growth.  The results obtained with normal  control 
mice are not shown because they were the same as those obtained with irradi- 
ated and bone marrow-restored controls. 
Specific  Neutralization  of Tumor  Growth  by Lymph Node  T  Cells.  The 
preceding result shows that the generation of concomitant immunity is thymus 
dependent. It was anticipated, therefore, that the lymph node draining the site 
of the  primary  tumor  would  contain  thymus-derived  lymphocytes  (T  cells) 
capable of causing local neutralization  of growth of a  tumor cell challenge  in 
normal test recipients.  The local Winn assay (11) was employed because of the 
difficulty experienced in attempting to transfer the immunity systemically. 
Fig. 5 shows the growth in the foot pads of test recipients of 5 ×  105 tumor cells 
mixed with 10, 25, or 50 times as many normal lymph node cells or "immune" 
lymph node cells from 10-day tumor-bearing donors. It can be seen that whereas 
the presence of normal lymph node cells, in all cases, actually caused a  slight 
enhancement  of tumor  growth,  immune  lymph  node  cells  caused  complete 40- 
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Fro.  2.  Concomitant immunity expressed by 10-day tumor bearers against a  10  "~, 10  6, and 
10  7 challenge  implant.  It was  only the  10  '~ implant that was  completely inhibited from 
growing, although significant immunity was also expressed against the larger implants. 
Means  ±  2 SE of five mice per time point. 
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suppression of tumor growth when present at a  50:1 ratio and partial,  though 
highly  significant,  suppression  when present  at  a  ratio  of 25:1.  Indeed,  even 
their presence at a  10:1 ratio caused some suppression of growth. 
Evidence that  the lymph node cells of tumor bearers responsible for tumor 
neutralization  were T cells is supplied in Fig. 6 where it can be seen that their 
capacity for neutralizing  tumor growth when present at a  50:1 ratio was com- 
pletely ablated by incubating them with anti-0 serum and complement. Incuba- 
tion with a high concentration of anti-Ig antibodies, in contrast, had no detecta- 
ble effect on their anti-tumor activity. The reason why lymphocytes treated with 
anti-0 serum caused an actual measurable enhancement of tumor growth is not 
known, but could be explained on the basis of published reports (14,  15) which 
show that under certain conditions lymphocytes can stimulate tumor growth. 
Indeed,  since the preceding results  revealed that  normal  lymphocytes stimu- 
lated growth of the tumor implant, it seems reasonable to suggest that the same 
type  of lymph  node  cells  were  present  in  the  immune  population,  survived 
treatment with anti-0 serum, and were free to cause enhancement. 
The specificity of the expression of the tumor-neutralizing  capacity of lymph 
node  T  cells  from  10-day  tumor  bearers  was  investigated  by  determining 
whether these cells would also neutralize  the growth of the apparently  unre- 
lated syngeneic BP3 fibrosarcoma when present at a  lymphocyte to tumor cell 
ratio of 50:1.  The results in Fig.  7 show that while a  high  level of anti-tumor 
activity was expressed against 5 x  105 cells of the homologous SA1 tumor, there 
was no significant suppression of growth of the same number of BP3 cells. To 
this extent, then, the expression of concomitant immunity to the SA1 sarcoma is 
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Fro.  3.  Evidence that syngeneic A/J mice generate levels of immunity comparable with 
those generated by AB6F1 mice. 10-day A/J tumor bearers caused almost complete inhibi- 
tion of growth of a  10  6 challenge implant. Means _+ 2 SE of five mice per time point. 
Neutralization  Does Not  Require  the  Presence of  Adherent  Accessory 
Cells.  It was shown in a  recent publication  (10) that neutralization  of tumor 
growth by lymphocytes from concomitantly immune mice is greatly reduced if 
the neutralization  test is performed in lethally irradiated  recipients,  or if the 
immune  lymphocytes  are  depleted  of glass  adherent  cells.  This  led  to  the 
suggestion (10) that the expression of concomitant immunity requires the partic- 
ipation  of a  radiosensitive  adherent  accessory  cell,  probably  the  monocyte- 
derived macrophage. Attempts to confirm these findings with the SA1 sarcoma 
were unsuccessful. 
Thus it can be seen in Fig.  8 that the removal of adherent cells by allowing 
them to stick to plastic Petri dishes caused no reduction in the capacity of 50 
times as many "immune" lymph node cells from 10-day tumor-bearing donors to 
neutralize the growth of 106 SA1 cells in normal test recipients. Likewise, Fig. 9 
shows that lethal gamma irradiation given to test recipients 48 h before employ- 
ing them in the neutralization test, in order to deplete them of blood monocytes 
(16),  caused no reduction in the capacity of donor lymph node cells to locally 
inhibit the growth of the tumor cell challenge. It seems fairly certain, therefore, 
that  neither  mature  adherent  macrophages  nor  a  mobile  pool  of monocyte- 
derived macrophages is essential for the expression of the local tumor-neutraliz- 
ing capacity of sensitized T cells in this tumor model. 
The Expression of  Immunity in the Tumor-Bearing Host is Nonspecific.  The 
foregoing results indicate that the lymph node draining the site of the primary 
tumor in concomitantly immune donors contains T lymphocytes that by them- 
selves can inhibit the growth of an implant of cells of the primary tumor in a ROBERT  J.  NORTH  AND  DAVID  P,  KIRSTEIN  281 
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FIa.  4.  Evidence that THXB mice developed a much lower level of  concomitant immunity 
to a  10  6 tumor cell challenge than control tumor bearers over 9 days of primary tumor 
growth. The control animals were lethally irradiated and bone marrow restored. They gave 
the same results as normal controls (not included). Means of five mice. 
normal  recipient,  and  that  the  neutralization  is  specific  for the  homologous 
tumor.  In apparent  contradiction to this,  the results in this section show that 
when tested in the tumor-bearing host itself, concomitant immunity was non- 
specific. 
It can be seen in Fig. 10, for instance, that besides being capable of inhibiting 
the growth of a  foot pad challenge of 5  ×  105 SA1 cells, mice bearing a  10 day 
primary SA1 tumor were also capable of significantly inhibiting the growth of a 
5 ×  105 challenge of cells of the MC5 or BP3 syngeneic fibrosarcomas. It can be 
seen  in  addition,  however,  that  when  the  size  of the  tumor  challenge  was 
increased  to  2  ×  106  tumor  cells,  the  expression  of concomitant  immunity 
appeared to be highly specific for the SA1 tumor. These results show, therefore, 
that concomitant immunity to the SA1 sarcoma possesses a nonspecific element, 
but that  it can only be expressed against relatively small  numbers of tumor 
cells.  It is obvious, therefore,  that  care should be taken  in designing  experi- 
ments for testing for the specificity of anti-tumor immunity. 
Dependence on Progressive Tumor Growth.  The implantation  of syngeneic 
tumor cells, more often than not, is followed by a period of latency before tumor 
growth becomes manifest.  There  is evidence to show (17),  moreover, that the 
length  of the latency period is inversely proportional  to the number of tumor 
cells  implanted.  This  knowledge  was  taken  advantage  of in  the  following 
experiments  to determine  whether the presence of a  deposit of immunogenic 
tumor  cells  during  a  long  period  of latency  is  in  itself enough  to evoke the 
generation of concomitant immunity,  or whether concomitant immunity is not 
generated until after the tumor begins to grow progressively. 282  T-CELL-MEDIATED  CONCOMITANT  IMMUNITY  TO  SYNGENEIC  TUMORS 
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Fro.  5.  The effect of mixing tumor cells with 50, 25, or 10 times as many lymph node cells 
from  10-day  concomitantly  immune  or  normal  mice  on  the  growth  of the  tumor  cells 
implanted in  a  normal  test recipient (Winn assay).  "Immune" lymph node cells caused 
substantial neutralization of tumor growth, in contrast to normal lymph node cells which 
caused a  slight enhancement of growth. Means of five mice. 
The  results  in  Fig.  11  indicate  that  the  host did not generate  concomitant 
immunity after implantation  of SA1 cells until after the period of latency had 
ended.  They  also  show  that  immunity  to  a  standard  tumor  cell  challenge 
increased  as  the  size  of the  primary  tumor  increased.  It  can  be  seen  that 
although 10-fold reductions in the number of tumor cells used to initiate tumors 
resulted in corresponding increases in the length of the period of latency, this 
had little effect on the rate of growth of the tumor after it eventually emerged. 
Changes in the level of concomitant immunity to a standard sized (10  e) second- 
ary  implant  (bar  graphs)  are  expressed  as  the  difference between the  5-day 
growth of the implant in tumor bearers and controls. The meaning of this assay 
can be appreciated from an examination  of Fig.  1. It is obvious, however, that 
since the challenge implant always grew at the same rate in control mice, any 
increase in the 5-day difference represented an increase in the capacity of the 
tumor-bearing host to inhibit growth of the tumor challenge.  The 5-day differ- 
ences were taken from complete growth curves of the challenge implants  and 
were used in order to avoid a  confusing presentation. 
The Concordant Generation of Anti-Bacterial Resistance.  It was shown in a 
previous publication  (18) that  the  growth  of any one  of three  transplantable 
murine tumors resulted in the acquisition of a systemically enhanced capacity 
for resisting  experimental  infection with the bacterial  parasite,  L.  monocyto- 
genes. It was shown in addition,  however, that the generation of anti-bacterial 
resistance  was preceded by a  tumor-induced  state of greatly suppressed anti- 
bacterial resistance,  the possible biological meaning  of which was adequately 
discussed (18, 19). The purpose of the experiments reported in this section was to 
obtain additional evidence for the proposition that the acquisition of enhanced 
macrophage-mediated anti-microbial resistance is a consequence of the genera- 
tion of concomitant immunity. ROBERT  J.  NORTH  AND  DAVID  P.  KIRSTEIN  283 
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FIG.  6.  Evidence that the lymph node cells that neutralize the growth of tumor cells are ~- 
positive T cells. The tumor suppressive action of 50 times as many immune lymph node cells 
on the growth of 10  ~ tumor cells implanted in a normal recipient was completely abolished 
by treating the lymph node cells with anti-~ serum and complement. In fact, anti-~ serum- 
treated lymphocytes caused enhanced growth of the tumor implant. Treatment with rabbit 
anti-Ig or with anti-~ serum absorbed with C3H brain (ABS ANTI-P) had no effect on the 
capacity of lymph node cells to neutralize tumor growth. Means of 5 mice. 
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FIG.  7.  The tumor-neutralizing capacity of immune lymph node cells was specific for cells 
of the primary tumor.  While lymph node cells from 10-day SA1 bearers were resistant to 
implant of 5  ×  10  s SA1 cells (50:1 ratio) they had no significant effect on the growth of the 
same number of BP3 cells. Means of five mice. 284  T-CELL-MEDIATED  CONCOMITANT  IMMUNITY  TO  SYNGENEIC  TUMORS 
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FIG. 8.  Removal of adherent lymph node cells by allowing them to react with a plastic 
surface had no effect on their capacity to cause inhibition of growth of tumor cells in a test 
recipient.  Means of five mice. 
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FIG.  9.  Lethal gamma irradiation of normal test recipients had no effect on the outcome of 
the tumor neutralization test performed in them 48 h  later. Immune lymph node cells were 
just as effective  in inhibiting tumor growth in irradiated mice  as they were in controls. 
Means of five mice. 
Fig.  12  shows  changes  in  resistance  (24  h  log~o  resistance)  to  a  standard 
intravenous Listeria  challenge  inoculum  against  time  after  initiating  tumors 
with different numbers of tumor cells.  As expected  from a  previous study  (18), 
subcutaneous  implantation  of tumor  cells  first  resulted  in  a  state  of greatly 
suppressed  anti-bacterial  resistance,  the development of which was faster with 
larger doses of tumor cells.  It can be seen,  however,  that this was followed by 
conversion  from  a  state  of suppressed,  to  a  state  of  significantly  enhanced, ROBERT  J.  NORTH  AND  DAVID  P.  KIRSTEIN  285 
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Fro.  10.  Evidence that mice concomitantly immune to the SA1 possessed a limited capac- 
ity to  restrict the growth of unrelated tumors. Mice with a  10 day SA1 primary tumor 
showed a significant  capacity to inhibit the growth of 5 x  10  5 BP3 or MC5 cells as well as 5 × 
10  5 SA1 cells, but did not express resistance to the heterologous tumors when the challenge 
dose was increased to 2  ×  l0  s. Means of five mice _+  2 SE. 
resistance and that the speed of this conversion depended on the emergence and 
progressive growth  of the tumor.  Thus the  shorter the period of latency,  the 
shorter the period of suppressed resistance and the faster the acquisition of anti- 
bacterial resistance.  When these results are compared with those in Fig.  11, it 
seems obvious that  the  acquisition  of anti-bacterial  resistance  was  a  conse- 
quence of the generation  of concomitant immunity.  It also seems certain that 
the generation of both mechanisms depended on a progressively growing tumor. 
Fig.  13 is included to show the meaning  of the 24-h differences in bacterial 
growth that  were used to compose Fig.  12.  It shows the  3-day growth of the 
standard bacterial inoculum in the livers of ]0-day tumor bearers and controls. 
It can be seen that the relatively small 24-h differences shown in Fig.  12 were 
indicative  of much  larger  differences at  later  times of infection.  Thus,  while 
bacterial  growth  was  completely suppressed  for  3  days  in  tumor  bearers,  it 
increased log linearly in controls. 286  T-CELL-MEDIATED  CONCOMITANT  IMMUNITY  TO  SYNGENEIC  TUMORS 
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Fza.  11.  Rate  of development  of concomitant  immunity  (bar  graphs)  to  a  10  6 tumor 
challenge in mice whose primary tumors were initiated with 10  4, 10  ~, or 10  6 tumor cells (line 
graphs). Concomitant immunity is expressed as the 5-day difference between growth of the 
challenge  in  tumor  bearers  and  controls  when  the  challenge  was  given  at  the  times 
indicated. Concomitant immunity was not generated during the period of latency. It was 
generated during rapid tumor growth and increased with increasing size of the primary 
tumor. Means of five mice. 
Discussion 
This paper shows that progressive growth of the SA1 sarcoma in syngeneic 
and semisyngeneic mice results in the systemic generation of a powerful mecha- 
nism of concomitant resistance to growth of a second implant of the same tumor. 
Employment of the Winn (11) neutralization assay showed, in addition, that the 
generation  of concomitant resistance  was associated with the production of 0- 
positive T cells in the draining lymph nodes which were capable of inhibiting the 
growth of tumor cells implanted in a normal test recipient. The neutralization of 
tumor  cells  was  specific,  was  accomplished  by lymph  node  cells  depleted  of 
adherent cells, and was expressed in test recipients that were lethally irradiated 
48 h before testing.  These results, together with those which showed that only 
marginal  levels of concomitant immunity were generated in mice made T-cell 
deficient by thymectomy and gamma  irradiation,  represent firm evidence for 
proposing that  concomitant immunity  to SA1 sarcoma is T-cell mediated and 
can be expressed by specifically sensitized T cells. The results are in agreement, 
therefore,  with the general conclusion by Kearney et al.  (9) that concomitant ROBERT  J.  NORTH  AND  DAVID  P.  KIRSTEIN  287 
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Fro.  ]2.  The generation of resistance (bar graphs) to a  104 intravenous challenge with L. 
monocytogenes during the growth of primary tumors initiated with 104, 10  '~, or 10  ~ SAt cells 
(line graphs). Shown are changes in anti-bacterial resistance (log~o resistance) as expressed 
as the difference between the 24 h growth of the parasite in the livers of tumor bearers and 
controls when the bacteria were given at the times indicated. Implantation of tumor cells 
first caused a striking suppression of anti-bacterial resistance. Subsequent conversion from 
a state of suppressed to a state of enhanced anti-bacterial resistance, however, depended on 
the emergence and progressive growth of the tumor. Means of five mice. 
immunity to murine fibrosarcomas is T-cell dependent. It does not support the 
other findings of these authors, however, that later stages of immunity are not 
expressed by T cells, but are expressed by other cells including B cells. It is well 
to realize, however, that their conclusions were based on results obtained with 
the in vitro microcytotoxicity  assay: an assay that requires an incubation period 
of long enough duration to allow the induction of an in vitro immune response, 
and which has been shown to give results that conflict with another in vitro 
assay (20), as well as with in vivo assays (21). For these and other reasons the 
microcytotoxicity assay has recently come under criticism (22-24). 
Our results do agree, however, with those which show (8) that concomitant 
immunity possesses a  nonspecific element when tested in the tumor-bearing 
host itself. The finding that this nonspecificity was only expressed against a 
relatively small number of  unrelated tumor cells, and that it was apparently not 288  T-CELL-MEDIATED  CONCOMITANT  IMMUNITY  TO  SYNGENEIC  TUMORS 
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Fro.  13.  Evidence that log,o 24 h anti-bacterial resistance shown in Fig. 12 was indicative 
of a  high  level  of anti-bacterial resistance.  Shown is  the  3-day  growth of a  2  x  104 
intravenous Listeria challenge in the livers of 10-day tumor bearers and controls. It can be 
seen that a 1.3 log increase in resistance at 24 h was indicative ofa 5 log difference at 72 h. 
Means of five mice _+  2 SE. 
expressed at all  against  larger  implants,  indicates  that  care should be taken 
when testing  the  specificity of anti-tumor  immunity.  The nonspecificity may 
have been the result of the sharing of common antigens between the tumor lines 
tested (25-27) while its limited strength of expression could result from the pos- 
sibility  (28) that  some tumor cells are more susceptible to cell-mediated lysis 
than others. It seems more reasonable to propose from the results of this study, 
however, that the nonspecific expression of resistance to the growth of heter- 
ologous tumor cells was the result of the possession by the concomitantly im- 
mune host of an activated macrophage system.  Since there is convincing evi- 
dence (29) that enhanced destruction ofL. monocytogenes depends on the posses- 
sion by the host of activated macrophages, there seems little doubt that the gen- 
eration of high levels of nonspecific anti-Listeria resistance during progressive 
tumor growth was the result of the generation of activated macrophages.  Fur- 
thermore, the striking temporal correlation between the generation of concomi- 
tant  immunity  and  the  generation  of  macrophage-mediated  anti-bacterial 
resistance is strong evidence for hypothesizing that macrophage activation is a 
T-cell-mediated consequence of the specific immune response to a progressively 
growing tumor.  Hence,  the  published  report  (30) that  mice bearing  the  syn- 
geneic Lewis lung carcinoma display enhanced resistance to Candida albicans 
infection,  and  publications  that  show that  tumor-bearing  humans  (31-33)  as 
well as animals  (34, 35) can display an activated reticuloendothelial system are 
evidenced by an enhanced capacity for clearing intravenously infused colloids. 
There is now adequate evidence for proposing that the possession of activated 
macrophages gives the host the capacity to nonspecifically inhibit the growth of 
syngeneic tumor cells as well as microbial parasites.  Thus,  it has been shown 
(36,  37) that animals with macrophages activated as a  result of infection with 
microorganisms  can retard the growth of a  tumor cell implant.  More convinc- 
ingly,  macrophages  harvested from such animals  have been shown on many 
occasions (36, 38-40) to possess nonspecific, potent anti-tumor activity in vitro. 
The  present  study,  then,  supplies  the  reciprocal  demonstration  that  macro- 
phage-mediated,  enhanced  anti-microbial  resistance  is  generated  via  an  im- ROBERT  J.  NORTH  AND  DAVID  P.  KIRSTEIN  289 
mune response to a tumor itself. It is apparent, therefore, that the macrophage 
has evolved to serve the dual role of protecting the host from colonization both 
by neoplastic cells and microorganisms. 
Even though the possession of activated macrophages  and cytotoxic T  cells 
appears to have no restrictive influence on the growth of the primary tumor, 
there is ample evidence for proposing that the presence of these components of 
concomitant immunity plays a  large part in determining the rate of establish- 
ment and the growth of metastases.  It has been shown, for instance,  that the 
rapid decay of concomitant immunity that occurs after surgical removal of the 
primary  tumor  is  followed by the  rapid  emergence  and  growth  of multiple 
metastases (5, 6). Again,  experiments performed in this laboratory (to be pub- 
lished), as well as those published by others (9), have revealed that metastases 
emerge  much  sooner  and  grow  much  faster  in  tumor-bearing  animals  that 
fail to develop concomitant immunity because of a deficiency of T cells. Again, 
animals  with  concomitant  immunity  are  more  resistant  than  normal  to the 
establishment of experimental metastases caused by the intravenous infusion of 
tumor  cells  (7,  41,  42).  It  seems highly  likely,  therefore,  that  the  results  of 
certain types of anti-cancer therapy may depend on whether or not the agents 
employed for therapy either partially or completely ablate an existing state of 
concomitant immunity. 
It is obvious that the contradiction suggested by the specificity of the neutrali- 
zation test and the nonspecificity displayed by the tumor-bearing donor is more 
apparent  than  real.  The  neutralization  test was  specific because it was per- 
formed in normal  test recipients without activated macrophages.  It shows,  in 
agreement with numerous publications (43), that sensitized T cells can act alone 
as the specific effectors of anti-tissue immunity.  It is almost certain,  however, 
that these cells act in concert with activated macrophages in expressing immu- 
nity in the concomitantly immune  host.  On the other hand,  no evidence was 
found for a  role for hu~noral  antibody,  as evidenced by the failure of either  a 
single or multiple infusions of tumor bearer's serum to retard the growth of a 
tumor  cell  challenge.  If  anything,  serum  caused  a  slight  enhancement  of 
growth.  On the basis of the present level of analysis, therefore, it seems fair to 
say that T-cell-mediated concomitant immunity generated against a progressive 
SA1 sarcoma shows striking similarities to T-cell mediated anti-bacterial immu- 
nity (28).  In both cases, the generation of sensitized T cells in the presence of 
replicating  antigen  results  in systemic activation  of macrophages that  conse- 
quently results in a  high level of nonspecific resistance to microbial parasites 
and neoplastic cells. 
Summary 
Progressive growth of the SA1 sarcoma was shown to result in the generation 
of a  state of concomitant resistance to growth of a  second implant of the same 
tumor. The responding lymph nodes of concomitantly immune mice were shown 
to  contain  P-positive T  cells  that  could  specifically neutralize  the  growth  of 
tumor cells in a normal test recipient. Nevertheless, the concomitantly immune 
host itself was capable to a limited extent of suppressing the growth of unrelated 
tumors. The generation of immunity, moreover, was associated with the genera- 290  T-CELL-MEDrATED  CONCOMITANT  IMMUNITY  TO  SYNGENEIC  TUMORS 
tion of a powerful state of macrophage-mediated, nonspecilic resistance to the 
bacterial  parasite,  Listeria  monocytogenes.  It  was  concluded  that  systemic 
macrophage activation was the consequence of the generation of T-cell-mediated 
immunity to the progressively growing tumor, and that this not only gave the 
host the capacity to inhibit the growth of unrelated tumors, but also to protect 
itself against  microbial  infection.  The results  give credence to the  view that 
macrophages  play  a  central  role in  defense against  microbial  and  neoplastic 
growth. 
We wish to thank Mr. J. F. Deissler for his expert technical effort. 
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